Comparative Pharmacology
Head-to-head clinical analysis: ANZUPGO versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZUPGO versus XTANDI.
ANZUPGO vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not established; no known pharmacological mechanism due to lack of clinical data.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
Not available. ANZUPGO is not a recognized drug in medical literature.
160 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; clinically, this supports intravenous administration every 6-8 hours for continuous coverage.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination constitutes the remainder (20-30%).
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic